Tourmaline Bio
TRML
TRML was delisted on the 27th of October, 2025.
48 hedge funds and large institutions have $77.3M invested in Tourmaline Bio in 2023 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 13 increasing their positions, 18 reducing their positions, and 13 closing their positions.
0.22% more ownership
Funds ownership: 6.18% → 6.4% (+0.22%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
3% less capital invested
Capital invested by funds: $79.7M → $77.3M (-$2.36M)
17% less funds holding
Funds holding: 58 → 48 (-10)
28% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 18
77% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$4.4M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
+$1.64M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$978K |
| 4 |
AAA
Affinity Asset Advisors
New York
|
+$586K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$540K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HighTower Advisors
Chicago,
Illinois
|
-$1.36M |
| 2 |
SM
Scoggin Management
New York
|
-$880K |
| 3 |
AI
Acuitas Investments
Seattle,
Washington
|
-$868K |
| 4 |
Renaissance Technologies
New York
|
-$715K |
| 5 |
Millennium Management
New York
|
-$481K |
TRML Hedge Fund Activity: Q3 2023 in Review
48 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Tourmaline Bio (TRML) for Q3 2023, worth a combined $77.3M — down 3% from $79.7M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of TRML and 3 opened new positions — a net loss of 10 holders — while 18 trimmed existing stakes and 13 added.
The largest buyer was Nantahala Capital Management, adding an estimated $4.4M. The largest seller was HighTower Advisors, exiting entirely with an estimated $1.36M sold.
- 48 institutional investors held Tourmaline Bio (TRML) as of Q3 2023, down from 58 in Q2 2023.
- Funds reported $77.3M of Tourmaline Bio stock for Q3 2023, down 3% quarter-over-quarter.
- 3 funds opened new Tourmaline Bio positions in Q3 2023 and 13 closed out, a net change of -10 holders.
- The largest Tourmaline Bio buyer in Q3 2023 was Nantahala Capital Management, an estimated $4.4M added.
- The largest Tourmaline Bio seller in Q3 2023 was HighTower Advisors, an estimated $1.36M sold.
Based on aggregated 13F filings for Q3 2023.